Company profile
INCYTE CORP
NASDAQ:INCYBiotechnology: Commercial Physical & Biological Resarch
Drug pipeline (25)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEMIGATINIB | approved | — | 13 | approved |
| Ruxolitinib Phosphate | approved | — | 4 | approved |
| PEMBROLIZUMAB | phase3 | — | 263 | active |
| RETIFANLIMAB | phase2_3 | — | 4 | completed, terminated, withdrawn |
| BARICITINIB | phase2 | — | 56 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (281)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00778700 | phase2 | completed | 2008-10-28 | 2009-06-26 | Incyte Corporation | A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis |
| NCT01072266 | phase1 | completed | 2010-01-01 | 2012-07-01 | Incyte Corporation | A Dose-escalation Study in Subjects With Advanced Malignancies |
| NCT01195311 | phase1 | completed | 2010-07-01 | 2013-05-01 | Incyte Corporation | A Dose-escalation Study in Subjects With Advanced Malignancies |
| NCT03920852 | phase1 | completed | 2019-05-30 | 2019-12-26 | Incyte Corporation | A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis |
| NCT06843408 | phase1_2 | active_not_recruiting | 2025-06-25 | 2027-01-06 | Incyte Corporation | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD |
FDA applications (7)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761163 | BLA | Incyte Corporation | ||||
Loading… | ||||||
| BLA 761334 | BLA | Incyte Corporation | ||||
Loading… | ||||||
| BLA 761411 | BLA | Incyte Corporation | ||||
Loading… | ||||||
| NDA 202192 | NDA | INCYTE CORP | ||||
Loading… | ||||||
| NDA 213736 | NDA | INCYTE CORP | ||||
Loading… | ||||||